| Autor: |
Johan Vekemans, Elizea Horne, Tandile Hermanus, Andrew Moultrie, Shabir A. Madhi, Teresa Lambe, Alane Izu, Clare L. Cutland, Faeezah Patel, Samuel van Eck, Merryn Voysey, Sarah C. Gilbert, Ayanda Nzimande, Asha Thombrayil, Carol Taoushanis, Shaun Barnabas, Vicky L. Baillie, Penny L. Moore, S Rhead, Mduduzi Masilela, Prudence Kgagudi, Tonya Villafana, Andrew J. Pollard, Thandeka Moyo-Gwete, Parvinder K. Aley, Anthonet Koen, Christian Kabasele Mukendi, S D Padayachee, Sutika Bhikha, Amit J Nana, Lee Fairlie, Carmen Briner, Keertan Dheda, Masebole Masenya, Q E Bhorat, Gaurav Kwatra, Aylin Oommen Jose |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.21203/rs.3.rs-322470/v1 |
| Popis: |
Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern1. People living with HIV (PLWH) are at increased risk for adverse COVID-19 outcomes compared with HIV-negative individuals2-5, and are a high-risk group for COVID-19 prevention4. The ChAdOx1 nCoV-19 (AZD1222) vaccine has demonstrated safety and efficacy against COVID-19 in clinical trials6-8. To date, there are no reports on the safety and immunogenicity of this, or any COVID-19 vaccine, in PLWH, and reports on the immunogenicity of COVID-19 vaccines in Africa are limited9. Here, we show comparable safety and immunogenicity of two doses of ChAdOx1 nCoV-19 between PLWH and HIV-negative individuals in South Africa. Furthermore, in PLWH previously exposed to SARS-CoV-2, antibody responses increased substantially from baseline following a priming dose, with modest increases after a booster dose. Full-length spike and receptor-binding domain IgG geometric mean concentrations after a single dose of ChAdOx1 nCoV-19 in PLWH previously exposed to SARS-CoV-2 were 6.49–6.84-fold higher than after two doses in those who were SARS-CoV-2 naïve at enrollment. Neutralizing antibody responses were consistent with the antibody-binding responses. This is the first report of a COVID-19 vaccine specific to PLWH, and specific to Africa, and demonstrates favorable safety and immunogenicity of ChAdOx1 nCoV-19 in PLWH. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
